Gemma Fisher

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 6

Top Topics

Cross Sectional

Duchenne Muscular Dystrophy

Top Venues

Expert opinion on therapeutic targets

Expert opinion on investigational drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Gemma Fisher, Laurane Mackels, Theodora Markati, Anna Sarkozy, Julien Ochala, Heinz Jungbluth, Sithara Ramdas, Laurent Servais
Early clinical and pre-clinical therapy development in Nemaline myopathy. Expert opinion on therapeutic targets (2022)
Theodora Markati, Gemma Fisher, Sithara Ramdas, Laurent Servais
Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA). Expert opinion on investigational drugs 31 (5) (2022)
Gemma Fisher, Laurane Mackels, Theodora Markati, Anna Sarkozy, Julien Ochala, Heinz Jungbluth, Sithara Ramdas, Laurent Servais
Early clinical and pre-clinical therapy development in Nemaline myopathy. Expert opinion on therapeutic targets 26 (10) (2022)
Gemma Fisher, Laurane Mackels, Theodora Markati, Anna Sarkozy, Julien Ochala, Heinz Jungbluth, Sithara Ramdas, Laurent Servais
Early clinical and pre-clinical therapy development in Nemaline myopathy. Expert opinion on therapeutic targets 26 (10) (2022)
Gemma Fisher, Laurane Mackels, Theodora Markati, Anna Sarkozy, Julien Ochala, Heinz Jungbluth, Sithara Ramdas, Laurent Servais
Early clinical and pre-clinical therapy development in Nemaline Myopathy. Expert opinion on therapeutic targets (2022)
Gemma Fisher, Laurane Mackels, Theodora Markati, Anna Sarkozy, Julien Ochala, Heinz Jungbluth, Sithara Ramdas, Laurent Servais
Early clinical and pre-clinical therapy development in Nemaline myopathy. Expert opinion on therapeutic targets 26 (10) (2022)